AbbVie announced Friday that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric...

Melinta Therapeutics, LLC (Melinta), today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin)  for the treatment of adult patients with acute bacterial skin...

Melinta Therapeutics, Inc. , a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the U.S. launch of intravenous and oral formulations...

By

Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results...